{
    "root": "2f7521e1-0e63-ec7a-e063-6394a90af954",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Valacyclovir Hydrochloride",
    "value": "20250303",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "VALACYCLOVIR HYDROCHLORIDE",
            "code": "G447S0T1VC"
        }
    ],
    "indications": "valacyclovir hydrochloride deoxynucleoside analogue dna polymerase inhibitor indicated : adult patients ( 1.1 ) cold sores ( herpes labialis ) genital herpes treatment immunocompetent patients ( initial recurrent episode ) suppression immunocompetent hiv-1-infected patients reduction transmission herpes zoster pediatric patients ( 1.2 ) cold sores ( herpes labialis ) chickenpox limitations ( 1.3 ) efficacy safety valacyclovir tablets established immunocompromised patients suppression genital herpes hiv-1-infected patients .",
    "contraindications": "valacyclovir tablets may given without regard meals . valacyclovir oral suspension ( 25 mg/ml 50 mg/ml ) may prepared extemporaneously 500 mg valacyclovir tablets pediatric patients solid form appropriate [ ( 2.3 ) ] .",
    "warningsAndPrecautions": "valacyclovir tablets usp , 500 mgare blue , film-coated , capsule shaped tablets “ f 82 ” one side plain otherside containing 556 mg valacyclovir hydrochloride equivalent 500 mg valacyclovir . bottles 10 ndc 72789-263-10 bottles 14 ndc 72789-263-14 bottles 28 ndc 72789-263-28 bottles 90 ndc 72789-263-90 store at20 oto 25 oc ( 68 oto 77 ) . [ usp controlled room temperature . ] dispense well-closed container defined usp .",
    "adverseReactions": "valacyclovir tablets contraindicated patients demonstrated clinically significant hypersensitivity reaction ( e.g . , anaphylaxis ) valacyclovir , acyclovir , component formulation [ ( 6.3 ) ] .",
    "indications_original": "Valacyclovir hydrochloride is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-1-infected patients Reduction of transmission Herpes Zoster Pediatric Patients (1.2) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use (1.3) The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients.",
    "contraindications_original": "Valacyclovir tablets may be given without regard to meals.\n                     \n                        Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500 mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate\n   \n    [see\n    \n     Dosage and Administration (2.3)]\n   \n    .",
    "warningsAndPrecautions_original": "Valacyclovir Tablets USP, 500 mgare blue, film-coated, capsule shaped tablets with “F 82” on one side and plain on the otherside containing 556 mg of valacyclovir hydrochloride equivalent to 500 mg of valacyclovir.\n \n                  \n                  Bottles of 10 NDC 72789-263-10\n  \nBottles of 14 NDC 72789-263-14\n \n                  Bottles of 28 NDC 72789-263-28\n  \nBottles of 90 NDC 72789-263-90\n \n                  \n                  \n                  \n                     Store at20 \n  oto 25 \n  oC (68 \n  oto 77 \n  oF). [See USP Controlled Room Temperature.]\n \n                  \n                  Dispense in a well-closed container as defined in the USP.",
    "adverseReactions_original": "Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation\n \n  [see\n  \n   Adverse Reactions (6.3)]\n \n  ."
}